Nagasaki COPD Trial Tests New Breathing Device

Introduction

A team at Nagasaki University Hospital in Japan is preparing a pilot trial to test a specific breathing device’s ability to improve exercise tolerance in people with COPD. Their study protocol outlines a method to isolate the effects of high-flow, non-oxygen enriched air on key physiological metrics, including carbon dioxide levels.

High-Flow Room Air Improves Walking Distance and CO2 Control

The research team, led by Chisato Fukushima and colleagues, designed a crossover trial where 20 patients will perform two 6-minute walk tests. One test uses the portable AIRVO3™ device, and one is performed without it. The primary measure is simple but critical: how far a patient can walk in six minutes. Secondary outcomes provide a detailed physiological picture, including transcutaneous carbon dioxide (PtcCO2), oxygen saturation, respiratory rate, and subjective breathlessness.

By setting the device to deliver room air with an FiO2 of 21%, the researchers intentionally remove oxygen supplementation from the equation. This isolates the therapeutic effect of high-flow mechanics. The AIRVO3™ washes out the anatomical dead space in the nasal passages and upper airways—the area where air sits but doesn’t participate in gas exchange. This action reduces the re-breathing of carbon dioxide-rich expired air, making each fresh breath more efficient. It also provides a slight positive airway pressure, which can keep smaller airways open and reduce the muscular work required to breathe. For a person with COPD, whose airways are obstructed and breathing muscles are overworked, this mechanical assistance could translate directly into more steps taken before exhaustion.

The Physiology: Reducing Work and Stabilizing CO2

The connection between easier breathing and improved exercise capacity hinges on two main mechanisms: reducing the work of breathing and better management of carbon dioxide. In COPD, patients often develop a rapid, shallow breathing pattern during exertion. This pattern is inefficient, increasing the work of breathing while failing to adequately ventilate the alveoli. It can also lead to a quicker rise in blood CO2 levels (hypercapnia), which contributes to the sensation of severe breathlessness.

NHF therapy directly addresses this. The high flow of fresh air reduces the drive to take rapid, shallow breaths by satisfying the body’s ventilatory demand more easily. The constant flush of the upper airway means less expired CO2 is present at the start of the next inhalation, improving ventilation efficiency. The study will measure PtcCO2 in real time during the walk test, specifically noting the “time to PtcCO2 ≥45 mmHg.” Delaying or preventing this CO2 threshold is a key indicator that the therapy is helping the patient manage gas exchange more effectively under stress.

This focus on CO2 management aligns with broader understanding of how carbon dioxide levels influence respiratory drive and perceived breathlessness. While this study uses a device, the principle of improving CO2 tolerance through more efficient breathing patterns is a cornerstone of many therapeutic breathing exercises.

Potential for Pulmonary Rehabilitation Without Oxygen

If proven effective and safe, the portable AIRVO3™ device could change practical approaches to pulmonary rehabilitation. Traditionally, patients with significant exertional dyspnea might require supplemental oxygen during exercise training. This pilot trial explores an alternative: using high-flow room air to achieve similar or better tolerance gains without oxygen tanks or concentrators.

The implications are practical. A lightweight, portable device could enable patients to engage in longer or more frequent walking sessions, potentially at home or in community settings, rather than strictly in clinical rehabilitation gyms. Improved physical activity directly counteracts the cycle of inactivity and deconditioning that worsens COPD outcomes. The trial will carefully assess patient-reported comfort and device-related discomfort, as these factors will determine whether patients will actually use the technology in daily life.

It is important to note this is a pilot study with a small sample size of 20 patients, designed to assess acute, within-day effects. Its results will inform whether a larger, more long-term trial is warranted. The crossover design, however, is strong for isolating the immediate effect of the intervention on an individual patient.

Connections to Foundational Breathing Science

The core principle tested here—that mechanical assistance to improve ventilation efficiency can enhance performance—resonates with foundational breathing science. Efficient breathing minimizes wasted effort and optimizes gas exchange, a goal shared by practices like diaphragmatic breathing and paced breathing exercises used in rehabilitation. The study’s specific focus on CO2 dynamics also connects to a wider body of research on how carbon dioxide levels affect respiratory physiology and even mental state.

For instance, research has shown that CO2 sensitivity can be linked to panic responses, and that chronic hyperventilation disorders are associated with low CO2 levels and systemic effects. While the NHF device addresses high CO2 in COPD, the broader relationship between CO2 tolerance, breathing patterns, and health is a active area of science. Furthermore, the concept of using a precise breathing intervention to improve a physiological outcome mirrors the approach found in resonance frequency breathing for stress and performance, where optimizing breath rate can influence heart rate variability.

Conclusion

The Nagasaki University protocol tests a targeted technological intervention to make breathing mechanically easier for people with COPD. By isolating the effect of high-flow room air, it seeks to provide a new, oxygen-independent option for improving exercise capacity and breaking the cycle of physical inactivity in chronic lung disease.

Sources:
https://pubmed.ncbi.nlm.nih.gov/41816455/
https://pubmed.ncbi.nlm.nih.gov/39935352/
https://pubmed.ncbi.nlm.nih.gov/39879158/